Sevabertinib
Highest phase reached
Phase 2
Drug type
Small molecule
- Listing at source
- Listed
- Highest phase reached
- Phase 2
- Drug type
- Small molecule
- Drug name
- Sevabertinib
- Molecular weight
- 484.94
- Structure (SMILES)
- COc1c(Cl)cccc1Nc1c(-c2ccncc2OC[C@@H]2COCCO2)[nH]c2c1C(=O)NCC2
- bay 2927088
- BAY-2927088
- bay2927088
- BAY2927088
- sevabertinib
- Sevabertinib
- Sevabertinib (BAY 2927088)
- sevabertinib [INN]
- SEVABERTINIB [USAN]
- Sevabertinib [WHO-DD]
- sevabertinib anhydrous
- Sevabertinib anhydrous
- sevabertinib inn
- sevabertinib usan
- sevabertinib who dd
- ATC classification codes
- L01EH06
Sources for recorded values
- CAS registry numbers
- 2521285-05-0
- ChEMBL ID
- CHEMBL6068074
- InChIKey
- VYQVHWNNPKOJEA-AWEZNQCLSA-N
- PubChem compound IDs
- 155234713
- RxNorm IDs (RxCUI)
- 2728187
- FDA ingredient codes (UNII)
- 2A7VPM5RWH
- Patents
- 1
- Designations
- 6
- Earliest recorded loss of exclusivity
- 10 Oct 2035
- First in class
- No
- Fast track
- No
- Breakthrough designation
- Yes
- Orphan designation
- No
- Priority review
- Yes
- Orphan exclusivity
- No
- Accelerated approval
- Yes
- Pharmacology name
- sevabertinib
- Type
- Synthetic organic
- Drug name stem
- -tinib
- Approval recorded by Guide to Pharmacology
- Yes
Investigated indications
- Condition
- Neoplasms
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000616
- Subject identifier
- D009369
- Condition identifier
- EFO_0000616
- Condition identifier
- MONDO_0005070
- Condition identifier
- MONDO_0005233
- Highest recorded phase
- 3
- Hydrogen bond acceptors
- 7
- Hydrogen bond donors
- 3
- Polar surface area
- 106.73
- Calculated partition coefficient (ALogP)
- 3.56
- Calculated partition coefficient (XLogP)
- 2.9
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Rule-of-five violations
- 0
- Rotatable bonds
- 7
- Heavy atoms
- 34
- Molecular formula
- C24H25ClN4O5
- Monoisotopic mass
- 484.1513476
- Natural product
- No
- 50419-397
Related records
Trials (11)
- A Study Evaluating How Moderate Liver Impairment Affects the Absorption, Distribution, Metabolism, and Elimination of Sevabertinib After a Single Oral Dose
- A Study to Learn About How BAY2927088 Affects the Level of Dabigatran or Rosuvastatin in the Blood When These Drugs Are Taken Together in Healthy Participants
- A Study to Learn About How BAY2927088 Affects the Level of Midazolam in the Blood When Both Drugs Are Taken Together in Healthy Participants
- A Study to Learn About How Food and Esomeprazole Affect the Level of BAY2927088 in the Blood When Taken Together in Healthy Participants
- A Study to Learn About How Itraconazole and Carbamazepine Affect the Level of BAY2927088 in the Blood When These Drugs Are Taken Together by Healthy Participants
- A Study to Learn How BAY2927088 is Taken up and Handled by the Body in Healthy Male Participants
- A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
- A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
- Expanded Access to Provide Sevabertinib (BAY 2927088) for the Treatment of Locally Advanced or Metastatic NSCLC With HER2 Mutation
- First in Human Study of BAY2927088 in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations in the Genes of Epidermal Growth Factor Receptor (EGFR) and/or Human Epidermal Growth Factor Receptor 2 (HER2)
- Phase 1 Study in Healthy Adults to See How Sevabertinib Changes Metformin Levels in the Body
In development for (1)
- Neoplasm Phase 2